Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 4/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.51 |
| ▸ | RELA | Q04206 | 4/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6258791 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKEPHX1 | |
| SCHEMBL4713242 | 0.90 | NFKB1 (0.54) | NFKB1NFKB2RELABTKEPHX1 | |
| SCHEMBL14459596 | 0.90 | NFKB1 (0.54) | NFKB1NFKB2RELABTKEPHX1 | |
| SCHEMBL4713236 | 0.90 | NFKB1 (0.54) | NFKB1NFKB2RELABTKEPHX1 | |
| SCHEMBL4713238 | 0.90 | NFKB1 (0.54) | NFKB1NFKB2RELABTKEPHX1 | |
| SCHEMBL14459580 | 0.90 | NFKB1 (0.54) | NFKB1NFKB2RELABTKEPHX1 | |
| SCHEMBL5601052 | 0.82 | NFKB1 (0.55) | NFKB1NFKB2RELABTKKMT2A | |
| SCHEMBL4520862 | 0.82 | NFKB1 (0.55) | NFKB1NFKB2RELABTKKMT2A | |
| SCHEMBL14586680 | 0.82 | NFKB1 (0.55) | NFKB1NFKB2RELABTKKMT2A | |
| SCHEMBL5600646 | 0.82 | NFKB1 (0.55) | NFKB1NFKB2RELABTKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370568-B1 | CHEMICAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2005-10-12 | — | — | EP | disclosed |
| US-20040162422-A1 | adenosine derivatives having an acetylene group in the 4' position, which are adenosine A1 agonists; treating ischaemic heart disease, peripheral vascular disease or stroke or patient suffering pain, a CNS disorder, sleep apnoea or emesis | HALL ADRIAN (GB) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162422-A1 | adenosine derivatives having an acetylene group in the 4' position, which are adenosine A1 agonists; treating ischaemic heart disease, peripheral vascular disease or stroke or patient suffering pain, a CNS disorder, sleep apnoea or emesis | ADORA1, ADORA2A, ADORA2B | NFKB1 1792/4885NFKB2 1786/4885RELA 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.